Skip to main content

Table 3 Number of patients with improvement from baseline BILAG B- and C-level activities

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

BILAG body system

6 weeksa

10 weeks

18 weeks

General (N = 14)b

6 (43%)

5 (36%)

2 (14%)

Mucocutaneous (N = 14)

11 (79%)

8 (57%)

6 (43%)

Neurological (N = 10)

7 (70%)

8 (80%)

6 (60%)

Musculoskeletal (N = 13)

9 (69%)

7 (54%)

4 (31%)

CV/Respiratory (N = 4)

3 (75%)

3 (75%)

3 (75%)

Vasculitis (N = 9)

4 (44%)

3 (33%)

3 (33%)

Renal (N = 4)

2 (50%)

1 (25%)

3 (75%)

Hematology (N = 12)

0 (0 %)

0 (0 %)

0 (0 %)

Overallc (N = 14)

13 (93%)

14 (100%)

13 (93%)

  1. aTwenty-four hours after fourth infusion. bN = number of patients with involvement in a particular body system at entry. cAs applied to any BILAG body system.